글로벌 류코트리엔 억제제 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

류코트리엔 억제제 시장 분석

류코트리엔 억제제 시장은 새로운 제형과 표적 치료법으로 상당한 진전을 목격하고 있으며, 효능이 강화되고 부작용이 줄었습니다. 환자는 증상 관리가 개선되고 악화가 감소하여 삶의 질이 향상됩니다. 이러한 진전은 알레르기성 비염과 천식에 대한 류코트리엔 억제제의 중요성이 커지고 있음을 강조하며, 호흡기 질환을 효과적으로 장기적으로 관리하려는 개인에게 더 밝은 전망을 약속합니다.                 

류코트리엔 억제제 시장 규모

글로벌 류코트리엔 억제제 시장 규모는 2023년에 23억 1,000만 달러로 평가되었으며, 2031년까지 37억 4,000만 달러에 도달할 것으로 예상되며, 2024년부터 2031년까지의 예측 기간 동안 CAGR은 6.22%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화

Leukotriene Inhibitors Market Definition

Leukotriene inhibitors are medications that prevent the action of leukotrienes, which are inflammatory molecules in the body. Through blocking leukotrienes, the leukotriene inhibitor drugs help reduce inflammation, swelling, mucus production, and constriction of the airways in conditions such as asthma and allergic rhinitis. They are often used as maintenance therapy to control symptoms and improve lung function in individuals with these conditions, offering an alternative or complement to other asthma medications including corticosteroids.           

Leukotriene Inhibitors Market Dynamics

Drivers

• Increasing Prevalence of Asthma and Allergic Rhinitis

Leukotriene inhibitors are commonly prescribed for conditions such as asthma and allergic rhinitis. As these conditions continue to rise globally, the demand for leukotriene inhibitors is expected to increase. As asthma and allergic rhinitis become more prevalent worldwide, the demand for leukotriene inhibitors is on the rise. For instance, according to the World Health Organization, asthma affects around 235 million people globally, and this number is increasing. Similarly, allergic rhinitis affects approximately 10-30% of the global population. With these conditions on the rise, there's a growing need for effective medications such as leukotriene inhibitors to manage symptoms and improve patients' quality of life.

• Growing Awareness about Respiratory Diseases

Increased awareness about respiratory diseases and their management has led to higher diagnosis rates. This, in turn, boosts the demand for medications such as leukotriene inhibitors. For instance, public health campaigns, educational programs, and media coverage have emphasized the importance of recognizing symptoms and seeking timely treatment. Consequently, more individuals are being diagnosed with these conditions, driving up the demand for medications such as leukotriene inhibitors, which play a crucial role in managing respiratory symptoms and improving patients' quality of life.

Opportunities

• Advancements in Drug Delivery Systems

Recent advancements in drug delivery systems, such as the development of once-daily formulations and novel inhaler devices, have significantly enhanced the convenience of administering medications. For instance, the introduction of Montelukast oral granules for children simplifies dosing, improving adherence among pediatric patients. These innovations not only streamline medication administration but also contribute to better patient compliance, possibly resulting in increased utilization of leukotriene inhibitor for conditions such as asthma and allergic rhinitis.

• Increasing Preference for Oral Medications

Leukotriene inhibitors are typically administered orally, which makes them more convenient for patients compared to inhalers or injections. This preference for oral medications can drive the growth of the leukotriene inhibitors market.  For instance, individuals with asthma may find it easier to adhere to a daily oral tablet regimen compared to using inhalers multiple times a day. This preference fosters increased adoption of leukotriene inhibitors, contributing to the expansion of the market. 

Restraints/Challenges

• Side Effects from Leukotriene Inhibitors

Safety concerns regarding liver toxicity and neuropsychiatric events associated with certain leukotriene inhibitors pose significant challenges for the market, raising apprehensions among both patients and healthcare providers. These adverse effects undermine trust in the medication's safety profile, potentially leading to decreased usage and market demand.

• Limited Efficacy in Some Patient Populations

Limited efficacy in certain patient populations, such as those with severe asthma leukotriene inhibitors or specific genetic profiles, reduces demand for leukotriene inhibitors. This limitation restricts market growth as these segments seek alternative treatments. Consequently, manufacturers may face challenges in market expansion and revenue generation due to the restricted effectiveness of their products in these populations. 

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Leukotriene Inhibitors Market Scope

The market is segmented on the basis of drug, indication, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Montelukast
• Zafirlukast
• Zileuton
• Others

 Indication

• Asthma
• COPD
• Allergic Rhinitis
• Others

 End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

 Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Leukotriene Inhibitors Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, drug, indication, distribution channel and end-user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the leukotriene inhibitors market, fueled by pioneering research and development initiatives and a substantial population susceptible to asthma. This dominance underscores the region's commitment to advancing healthcare solutions for managing respiratory conditions effectively and improving patient outcomes.

Asia-Pacific is witnessing significant growth in the leukotriene inhibitors market, propelled by expanding healthcare infrastructure, a proliferation of generic manufacturers, and increasing government support and specialist communities' initiatives. This trend underscores a favourable environment for market expansion throughout the forecasted period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Leukotriene Inhibitors Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• Mallinckrodt plc (영국)
• Sun Pharmaceutical Industries Ltd. (인도)
• 노바티스 AG(스위스)
• 엔도 파마슈티컬스 주식회사(아일랜드)
• 지두스 카딜라(인도)
• 마일런 NV(미국)
• Mayne Pharma Group Limited(호주)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Amneal Pharmaceutical Inc (미국)
• Avet Pharmaceuticals Inc. (미국)
• Aurobindo Pharma(인도)
• GSK plc (영국)
• 알미랄, SA(스페인)
• Merck & Co., Inc. (독일)
• Bausch Health(캐나다)
• Sandoz International GmbH(독일)
• 파이저 주식회사(미국)
• 아스트라제네카(영국)
• 사노피(프랑스)
• Bayer AG(독일)
• 맥케슨 코퍼레이션(미국)

류코트리엔 억제제 시장의 최신 개발

• 2023년 3월, Celtaxsys는 Acebilustat(CTX-4430)에 대한 실용적, 다중군, 적응적, 맹검, 무작위 위약 대조 플랫폼 시험의 2상을 마쳤습니다. 이 시험은 표준 지지 치료와 비교하여 COVID-19 외래 환자의 질병 해결 또는 바이러스 부하 중단 시간을 단축하는 데 있어 다양한 조사 치료제의 효능을 평가하는 것을 목표로 했습니다. 이 접근 방식은 병원 환경 밖에서 COVID-19를 관리하기 위한 잠재적 치료법에 대한 통찰력을 제공합니다.

SKU-53832